Krystal Biotech, Inc. KRYS Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Krystal Biotech, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s cash ratio?
- Krystal Biotech, Inc. (KRYS) reported cash ratio of 4.7× in Q1 2026.
- How has Krystal Biotech, Inc.'s cash ratio changed year-over-year?
- Krystal Biotech, Inc.'s cash ratio increased by 19.7% year-over-year, from 3.9× to 4.7×.
- What is the long-term trend for Krystal Biotech, Inc.'s cash ratio?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s cash ratio has grown at a -22.6% compound annual growth rate (CAGR), from 17.4× to 4.8×.
- What does cash ratio mean?
- How much of its short-term bills the company could pay with cash on hand right now.
- How do you interpret cash ratio?
- A buffer against stress, but persistently high cash ratios can indicate under-deployed capital. Interpret alongside the company's capital-allocation strategy.
- How does cash ratio compare across companies?
- Varies widely by business model and treasury policy; best read against the company's own history.